Lavipharm (FRA:BXA0) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BXA0 Lavipharm SA FRA:BXA0
79 GF Score
Price €1.55
GF Value €1.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lavipharm Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lavipharm Valuation Rank Related Terms

FRA:BXA0
79GF Score
Lavipharm SA FRA:BXA0
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lavipharm (FRA:BXA0) Overvalued in 2026?

Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued. The current stock price of €1.55 is trading 50.5% above its estimated GF Value™ of €1.03. GuruFocus considers Lavipharm to be Significantly Overvalued.

Key valuation signals for FRA:BXA0:

  • Valuation Rank:
  • GF Value™: €1.03 vs. price of €1.55 (50.5% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the FRA:BXA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lavipharm Business Description

Other Exchanges LAVI:Greece
Address 12, Agias Marinas Street, PO Box 59, Paiania, GRC, 19002
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
79GF Score

Get the complete analysis for FRA:BXA0

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€1.03
GF Value